Syntaxin Molecules: Therapeutics not neurotoxins
Neurotoxin |
Syntaxin molecules |
|
 Most potent acute lethal toxin known |
 Not a toxin |
|
| Narrow therapeutic window (less than 10x) |
Wide therapeutic window (greater than 103) vs botulinum neurotoxin |
|
| Requires local administration |
Range of delivery options (including systemic admin) |
|
| Peripheral cholinergic (neuromuscular) target only |
All cell types potential targets |
|
| Clinically effective in a limited number of indications |
Clinically applicable across a wide range of indications |
|
| Variable duration of action (e.g. 1 week to 3 months) |
Variable duration of action (e.g. 1 week to 3 months) |
|
| Intracellular SNARE cleavage mode of action (Endopeptidase) |
Intracellular SNARE cleavage mode of action (Endopeptidase) |
|
| Potential to inhibit release of multiple mediators |
Potential to inhibit release of multiple mediators |
|
| No cellular toxicity |
No cellular toxicity |
|
| High potency enabling low dosing |
High potency enabling low dosing |
|
| Protein produced as a complex |
Recombinantly-produced pure protein |
|
| Clostridial (spore-forming) host organism |
Use of standard bacterial hosts (e.g. E. Coli) |
|
| Known natural product, not patented |
Proprietary, patented molecules |
Denotes that this particular feature is 'safe' or beneficial.
Denotes the 'danger' or disadvantage of the toxins.